These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 18154542

  • 1. Breakpoints for intravenously used cephalosporins in Enterobacteriaceae--EUCAST and CLSI breakpoints.
    Kahlmeter G.
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():169-74. PubMed ID: 18154542
    [Abstract] [Full Text] [Related]

  • 2. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
    Jean SS, Lee WS, Bai KJ, Lam C, Hsu CW, Yu KW, Liao CH, Chang FY, Ko WC, Wu JJ, Chen YH, Chen YS, Liu JW, Lu MC, Liu CY, Chen RJ, Hsueh PR.
    J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
    [Abstract] [Full Text] [Related]

  • 3. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI screening parameters for the detection of extended-spectrum β-lactamase production in clinical Enterobacteriaceae isolates.
    Polsfuss S, Bloemberg GV, Giger J, Meyer V, Hombach M.
    J Antimicrob Chemother; 2012 Jan; 67(1):159-66. PubMed ID: 21972269
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing extended spectrum beta-lactamases.
    Jones RN, Craig WA, Ambrose PG, Dudley MN, Pottumarthy S.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):235-46. PubMed ID: 16105568
    [Abstract] [Full Text] [Related]

  • 6. Consequences of revised CLSI and EUCAST guidelines for antibiotic susceptibility patterns of ESBL- and AmpC β-lactamase-producing clinical Enterobacteriaceae isolates.
    Hombach M, Mouttet B, Bloemberg GV.
    J Antimicrob Chemother; 2013 Sep; 68(9):2092-8. PubMed ID: 23633681
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Breakpoints for extended-spectrum beta-lactamase-producing Enterobacteriacae: pharmacokinetic/pharmacodynamic considerations.
    MacGowan A.
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():166-8. PubMed ID: 18154541
    [Abstract] [Full Text] [Related]

  • 9. Reevaluation of the cefepime minimal inhibitory concentrations and disk diffusion test zone diameter relationship for a worldwide collection of Enterobacteriaceae enriched for extended-spectrum beta-lactamase-producing organisms.
    Pottumarthy S, Deshpande LM, Sader HS, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):95-9. PubMed ID: 15964496
    [Abstract] [Full Text] [Related]

  • 10. Breakpoints for carbapenemase-producing Enterobacteriaceae: is the problem solved?
    Cantón R, Canut A, Morosini MI, Oliver A.
    Enferm Infecc Microbiol Clin; 2014 Dec; 32 Suppl 4():33-40. PubMed ID: 25542050
    [Abstract] [Full Text] [Related]

  • 11. beta-Lactams without a suicide inhibitor.
    Giamarellou H.
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():194-7. PubMed ID: 18154547
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Occurrence of extended spectrum beta-lactamases among Enterobacteriaceae spp. isolated at a tertiary care institute.
    Kumar MS, Lakshmi V, Rajagopalan R.
    Indian J Med Microbiol; 2006 Jul; 24(3):208-11. PubMed ID: 16912442
    [Abstract] [Full Text] [Related]

  • 14. Orthodox and unorthodox clavulanate combinations against extended-spectrum beta-lactamase producers.
    Livermore DM, Hope R, Mushtaq S, Warner M.
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():189-93. PubMed ID: 18154546
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Pseudomonas aeruginosa and beta-lactam antibiotics at the time of Europe].
    Cavallo JD, Mérens A.
    Pathol Biol (Paris); 2008 Jan; 56(7-8):435-8. PubMed ID: 19019568
    [Abstract] [Full Text] [Related]

  • 18. High resistance to fourth-generation cephalosporins among clinical isolates of Enterobacteriaceae producing extended-spectrum beta-lactamases isolated in Portugal.
    Fernandes R, Gestoso A, Freitas JM, Santos P, Prudêncio C.
    Int J Antimicrob Agents; 2009 Feb; 33(2):184-5. PubMed ID: 18926667
    [No Abstract] [Full Text] [Related]

  • 19. Impact of CLSI and EUCAST Cefepime breakpoint changes on the susceptibility reporting for Enterobacteriaceae.
    Bork JT, Heil EL, Leekha S, Fowler RC, Hanson ND, Majumdar A, Johnson JK.
    Diagn Microbiol Infect Dis; 2017 Dec; 89(4):328-333. PubMed ID: 29031525
    [Abstract] [Full Text] [Related]

  • 20. Living with ESBLs. Introduction.
    Cornaglia G, Garau J, Livermore DM.
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():1-2. PubMed ID: 18154523
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.